Drug Profile
Oxytocin - Tonix Pharmaceuticals
Alternative Names: Intranasal potentiated oxytocin - Tonix Pharmaceuticals; Oxytocin intranasal - Tonix Pharmaceuticals; TI-001; TI-114; TNX-1900; TNX-2900Latest Information Update: 27 Mar 2024
Price :
$50
*
At a glance
- Originator Trigemina
- Developer Massachusetts General Hospital; Tonix Pharmaceuticals Holding Corp; Trigemina
- Class Amides; Amines; Analgesics; Antihaemorrhagics; Antihyperglycaemics; Antimigraines; Behavioural disorder therapies; Hormones; Macrocyclic lactams; Obesity therapies; Oxytocics; Pyrrolidines
- Mechanism of Action Calcitonin gene-related peptide antagonists; Oxytocin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Prader-Willi syndrome
Highest Development Phases
- Phase II Binge-eating disorder; Migraine; Obesity; Pervasive child development disorders; Social phobia
- Phase I Prader-Willi syndrome
- Preclinical Pain
- Research Diabetes mellitus; Glucose intolerance; Insulin resistance
- No development reported Headache; Trigeminal neuralgia
Most Recent Events
- 25 Mar 2024 The US FDA grants rare pediatric disease designation to intranasal oxytocin for the treatment of Prader-Willi syndrome in children and adolescents
- 04 Dec 2023 Oxytocin is available for licensing as of 04 Dec 2023
- 04 Dec 2023 US FDA approves IND application for oxytocin in Prader Willi syndrome